Abstract 887P
Background
Locally advanced laryngeal carcinoma is treated by concomitant chemotherapy and radiotherapy then surgery whenever possible. Most patients between 60-70 years refuse surgery, therefore, we designed a treatment in order to postpone or evade the surgical option in elderly patients with T3 and T4 disease.
Methods
In this prospective phase II trial, we included 120 patients diagnosed with locally advanced laryngeal carcinoma (84 patients with T3 disease versus 36 patients with T4 disease) aged between (60-74 years) 67 years in median. Study was started by weekly paclitaxel at a fixed dose of 150mg and carboplatin AUC4 taken on days 1,8 and 15 of a 21-day schedule, cycles were repeated for 6 times. Then patients were evaluated by CT scan and laryngoscopy. Complete responders, partial and non-responders are referred to concomitant radiotherapy (60 Gy) with weekly cisplatin at 50mg for 6 weeks. Patients were followed up for a median of 42 months (38-57 months). Study end point was objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) for 3 years. Secondary end point was toxicity profile.
Results
ORR was observed in 116 patients (96.6%) evaluated by clinical exam, CT scan and laryngoscopy. Complete clinical response was documented in 87 patients after completion of chemotherapy 72.5% (95% CI: 66.2-79.1) and 27.5% partial responders (95% CI: 23.4-31.7). At 3 years of follow-up, PFS was 95% (95% CI: 92.7-98.8) (p value 0.001) while the OS at 3 years was 95%. We have lost 4 patients who died after hospitalization for severe neutropenia and renal failure. Surgery was deleted as an option in this category of patients. The toxicity profile was composed of different grades of neutropenia/thrombocytopenia and anemia. Reversable acute renal failure was seen in 5 patients as well as alopecia. Peripheral neuropathy with different grades was documented in 92 patients.
Conclusions
Neoadjuvant chemotherapy followed by concomitant chemo-radiotherapy in the light of feasibility and acceptable toxicity profile can be a substitution for surgery in elderly patients with locally advanced laryngeal carcinoma taking into consideration the good tolerance and the modest toxicity profile.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received anyfunding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
890P - Stereotactic body radiation therapy combined with chemotherapy and tislelizumab in metastatic nasopharyngeal carcinoma: A prospective, single-arm, phase II study
Presenter: Tongxin Liu
Session: Poster session 02
891P - Pembrolizumab and olaparib in recurrent/metastatic, platinum resistant nasopharyngeal cancer: The POINT study
Presenter: Cristina Gurizzan
Session: Poster session 02
892P - Camrelizumab plus dalpiciclib in anti-PD-1 refractory recurrent or metastatic nasopharyngeal carcinoma
Presenter: Xi Ding
Session: Poster session 02
894P - AXEL: AXitinib-avELumab combination in recurrent or metastatic (RM) nasopharyngeal cancer (NPC)
Presenter: Edwin Hui
Session: Poster session 02
895P - Cost effectiveness of stereotactic ablative radiotherapy (SABR) alone in comparison with systemic treatment and SABR in oligometastatic head and neck cancer in the GORTEC 2014-04 OMET randomized phase II study
Presenter: Juliette Thariat
Session: Poster session 02
896P - Day of the week of chemotherapy (CT) during concurrent chemoradiation (CRT) for oropharyngeal squamous cell carcinoma (OPSCC)
Presenter: Camilla Hoff
Session: Poster session 02
897P - Tumor habitat-based MRI features assessing early response in locally advanced nasopharyngeal carcinoma
Presenter: Jinling Yuan
Session: Poster session 02
898P - Real-world overall survival (OS) in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC) in Asia: A literature review
Presenter: Darren Wan-Teck Lim
Session: Poster session 02
899P - Safety and efficacy of a novel CAR-T cell therapy (BRG01) targeting the Epstein-Barr Virus envelope glycoprotein in advanced metastatic nasopharyngeal cancer patients
Presenter: Li Zhang
Session: Poster session 02